Identifying the mechanisms of antidepressant drug action in mice lacking brain serotonin
Main supervisor: Prof. Dr. Golo Kronenberg, Charité
Second supervisor: Prof. Dr. Michael Bader, MDC
Student: Markus Petermann, Helmholtz Graduate School Molecular Cell Biology, MDC
Project summary: Serotonin deregulation plays a physiologic role in neurogenic decline and mood disorders. In the case of depression, manipulation of serotonin leads to clinical improvement associated with a delayed increase in hippocampal neurogenesis and BDNF signaling. However, commonly used serotonin-based antidepressants are broadly acting and we still lack a clear understanding of the underlying therapeutic mechanisms. We propose new insights that will come from examining the contribution of serotonin to the effects of pro-/anti-depressive stimuli on candidate mechanisms in the brain and behavior. We will take advantage of the Tph2-/- mouse model that lacks brain serotonin and explore the responds to i) antidepressant treatment, ii) psychological stress (chronic stress paradigm), and iii) electroconvulsive therapy. Identifying the pathways of serotonin activity, BDNF, and other neurotransmitter systems that directly mediate hippocampal neurogenesis can be used to define new therapeutic targets. The long-term goal is to identify antidepressant mechanisms and to facilitate a design of alternative approaches for the treatment of depression or age-related decline in learning and memory.